Last reviewed · How we verify
NCT04393805: HETHICO
Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto
trial testing Low Molecular Weight Heparin in COVID-19 in 744 participants. Completed in 26 February 2021.
26 February 2021
Quick facts
| Lead sponsor | Quovadis Associazione |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 744 |
| Start date | 1 June 2020 |
| Primary completion | 26 February 2021 |
| Estimated completion | 26 February 2021 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Low Molecular Weight Heparin — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Hypercoagulability — all drugs for Hypercoagulability →
Sponsor
Quovadis Associazione — full company profile →
Who can join
18 and older, any sex, with COVID-19 or Hypercoagulability. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The HETHICO study aims to collect retrospectively documented clinical information on patients hospitalized in Veneto Region (Italy) for SARS-COVID-2 infection in 2 types of settings, medical environment (COORTE MED), and intensive / sub-intensive (COORTE ICU), to assess the safety and possible efficacy of the anticoagulant treatments used for thromboprophylaxis, or in preventing thrombotic complications related to hospitalization from COVID-19.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19.
Bernard I, Limonta D, Mahal LK, Hobman TC. · · 2020 · cited 128× · PMID 33375371 · DOI 10.3390/v13010029 -
COVID-19, coagulopathy and venous thromboembolism: more questions than answers.
Marietta M, Coluccio V, Luppi M. · · 2020 · cited 67× · PMID 32653981 · DOI 10.1007/s11739-020-02432-x -
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication.
Ning Q, Wu D, Wang X, Xi D, et al · · 2022 · cited 64× · PMID 35197452 · DOI 10.1038/s41392-022-00907-1 -
Thromboinflammation in COVID-19 acute lung injury.
Mitchell WB. · · 2020 · cited 54× · PMID 32653469 · DOI 10.1016/j.prrv.2020.06.004 -
Prophylactic anticoagulants for people hospitalised with COVID-19.
Flumignan RL, Tinôco JDS, Pascoal PI, Areias LL, et al · · 2020 · cited 42× · PMID 33502773 · DOI 10.1002/14651858.cd013739 -
Anticoagulants for people hospitalised with COVID-19: a rapid review
Flumignan RL, Civile VT, Tinôco JDS, Pascoal PI, et al · · 2022 · cited 41× · PMID 35244208 · DOI 10.1002/14651858.cd013739.pub2 -
Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.
Obi AT, Barnes GD, Napolitano LM, Henke PK, et al · · 2021 · cited 30× · PMID 32916371 · DOI 10.1016/j.jvsv.2020.08.030 -
COVID-19 associated complications and potential therapeutic targets.
Monpara JD, Sodha SJ, Gupta PK. · · 2020 · cited 21× · PMID 32926918 · DOI 10.1016/j.ejphar.2020.173548
Verify or expand the search:
- PubMed search for NCT04393805
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Low Molecular Weight Heparin
Trials testing the same drug.
- NCT03120715 — Pregnancy Outcome of Women Using Low Molecular Weight Heparin Before Frozen-thawed Embryo Transfer · Phase 4 · unknown
- NCT02238444 — Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy · Phase 4 · unknown
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Quovadis Associazione trials
Trials by the same sponsor.
- NCT06973902 — The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF · recruiting
- NCT04359212 — Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 · completed
- NCT04329390 — MAC Project, Monitoring of AntiCoagulant Therapies (MAC) · completed
- NCT03428711 — Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04393805 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Quovadis Associazione
- Last refreshed: 18 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04393805.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing